Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis

Nature Medicine

Volumn 6, Issue 6, 2000, Pages 643-651

  Yan, Shi Du ^a   Zhu, Huaijie ^a   Zhu, Aiping ^a   Golabek, Adam ^b   Du, Hong ^a   Roher, Alex ^c   Yu, Jin ^d   Soto, Claudio ^e,f   Schmidt, Ann Marie ^a   Stern, David ^a   Kindy, Mark ^d  

^a Surgeons of Columbia University ^*  (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d LEXINGTON VA MEDICAL CENTER   (United States)

^e SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^f UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; SERUM AMYLOID A;

AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SPLEEN;

AMYLOID; AMYLOIDOSIS; ANIMALS; CELL LINE; GLYCOPROTEINS; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HUMANS; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MONOCYTES; NF-KAPPA B; RABBITS; RECEPTORS, IMMUNOLOGIC; SERUM AMYLOID A PROTEIN; SILVER NITRATE; SPLEEN;

ANIMALIA;

EID: 0001358519     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/76216     Document Type: Article

References (43)

1. Sipe, J. Amyloidosis. Annu. Rev. Biochem. 61, 947-975, 1992
2. Falk, R., Comenzo, R. & Skinner, M. The systemic amyloidoses. N. Engl. J. Med. 337, 898-908, 1997
3. Gillmore, J., Hawkins, P. & Pepys, M. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br. J. Haematol. 99, 245-256 (1997).
4. Hoshii, Y. et al. Amyloid A protein amyloidosis induced in ApoE-deficient mice. Am. J. Pathol. 151, 911-917 (1997).
5. Wisniewski, T. & Frangione, B. ApoE: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135:235-238 (1992).
6. Kindy, M. & Rader, D. Reduction in amyloid A amyloid formation in apolipoprotein E-deficient mice. Am. J. Pathol. 152, 1387-1395 (1998).
7. Kindy, M., King, A., Perry, G., deBeer, M. & deBeer, F. Association of apolipoprotein E with murine amyloid A protein amyloid. Lab. Invest. 73, 469-475 (1995).
8. Hawkins, P., Tennent, G., Woo, P. & Pepys, M. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin. Exp. Immunol. 84, 308-316 (1991).
9. Botto, M. et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med. 3, 855-859 (1997).
10. Kisilevsky, R. et al. Arresting amyloidosis in vivo using small molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nature Med. 1, 143-148 (1995).
11. Rysava, R., Merta, M., Tesar, V., Jirsa, M. & Zima, T. Can serum amyloid A or macrophage colony stimulating factor serve as a marker of amyloid formation? Biochem. Mol. Biol. Int. 47, 845-850 (1999).
12. Schmidt, A-M., Yan, S-D., Wautier, J-L. & Stern, D. Activation of RAGE: a mechanism for chronic dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84, 489-497 (1999).
13. Hofmann, M. et al. RAGE mediates a novel proinflammatory axis: the cell surface receptor for 5100/calgranulin polypeptides. Cell 97, 889-901 (1999).
14. Yan, S-D., Roher, A., Schmidt, A-M. & Stern D. Cellular cofactors for amyloid beta-peptide induced by cell stress: moving from cell culture to in vivo. Am. J. Pathol. 155, 1403-1411 (1999).
15. Shiroo, M., Kawahara, E., Nakanishi, I. & Migita, S. Specific deposition of serum amyloid A protein 2 in the mouse. Scand. J. Immunol. 332, 721-728 (1998).
16. Strachen, A., deBeer, F., van der Westhuyzen, D. & Coetzee, G. Identification of three isoform patterns of human serum amyloid A protein. Biochem. J. 250, 203-207 (1988).
17. DeBeer, M., deBeer, F., McCubin, W., Kay, C. & Kindy, M. Structural prerequisites for serum amyloid A fibril formation. J. Biol. Chem. 268, 20606-20612 (1993).
18. Sipe, J. et al. Characterization of the inbred CE/J mouse strain as amyloid resistant. Am. J. Pathol. 143, 1480-1485 (1993).
19. Park, L. et al. Suppression of accelerated diabetic atherosclerosis by sRAGE. Nature Med. 4, 1025-1031 (1998).
20. Bocchini, V. et al. An immortalized cell line expresses properties of activated microglial cells. J. Neurosci. Res. 31, 616-621 (1992).
21. Yan, S-D. et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691 (1996).
22. Suffredini, A., Fantuzzi, G., Badolato, R., Oppenheim, H. & O'Grady, N. New insights into the biology of the acute phase response. J. Clin. Immunol. 19, 203-214 (1999).
23. Collins, T. Endothelial nuclear factor kB and the initiation of the atherosclerotic lesion. Lab. Invest. 68, 499-508 (1993).
24. Husebekk, A., Skogen, B., Husby, G. & Marbaug, G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scan. J. Immunol. 21, 283-287 (1985).
25. Kirschner, D., Abraham, C. & Selkoe, D. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibrils in Alzheimer's disease indicates cross-beta conformation. Proc. Natl. Acad. Sci. USA 83, 503-507 (1986).
26. Kimball, M., Sato, A., Richardson, J., Rosen, L. & Low, B. Molecular conformation of erabutoxin b. Biochem. Biophys. Res. Comm. 88, 950-956 (1979).
27. Dickson, D. Microglia in Alzheimer's disease and transgenic models. Am. J. Pathol. 154, 1627-1631 (1999).
28. Uchihara, T., Akiyama, H., Kondo, H. & Ikeda, K. Activated microglial cells are colocalized with perivascular deposits of amyloid beta-peptide in Alzheimer's disease brain. Stroke 28, 1948-1950 (1997).
29. Yan, S-D. et al. Amyloid beta peptide-RAGE interaction elicits neuronal expression of M-CSF: a proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. USA 94, 5296-5301 (1997).
30. Fixe, P. & Praloran, V. M-CSF: haematopoietic growth factor or inflammatory cytokine? Cytokine 10, 32-37 (1998).
31. Hamilton, J. CSF-1 signal transduction. J. Leukoc. Biol. 62:145-155 (1997).
32. Hume, D. et al. Regulation of CSF-1 receptor expression. Mol. Reprod. Dev. 46, 46-52 (1997).
33. Ando, Y. et al. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem. Biophys. Res. Commun. 232, 497-502 (1997).
34. Ritthaler, U. et al. Expression of RAGE in peripheral occlusive vascular disease. Am. J. Pathol. 146, 688-694 (1995).
35. Wautier, J-L. et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble RAGE blocks hyperpermeability. J. Clin. Invest. 97, 238-243 (1996).
36. Rudderman, N., Williamson, J. & Brownlee, M. Glucose and diabetic vascular disease. FASEB J. 6, 2905-2914 (1992).
37. Brett, J. et al. Tissue distribution of RAGE: expression in smooth muscle, cardiac myocytes, and neural tissue in addition to the vasculature. Am. J. Pathol. 143, 1699-1712 (1993).
38. Hori, O. et al. RAGE is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752-25761 (1995).
39. Schafer, B. & Heizmann, C. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem. Sci. 21, 134-140 (1996).
40. Wang, H. et al. HMG1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251, 1999.
41. Taguchi, A. et al. Blockade of RAGE/amphoterin axis suppresses tumor growth and metastases. Nature (in the press).
42. Prelli, F., Pras, M. & Frangione, B. Degradation and deposition of amyloid A fibrils are tissue specific. Biochemistry 26, 8251-8256 (1987).
43. Klotz, I. & Hunston, D. Mathematical models for ligand-receptor binding. J. Biol. Chem. 258, 11442-11445 (1984).